Monica Shokeen, Ph.D.

Assistant Professor

Molecular Cell Biology Program
Biochemistry, Biophysics, and Structural Biology Program
Immunology Program

  • 314-362-8979

  • 8225


  • Development and evaluation of small- and macro-molecular agents for multi-modal molecular imaging of cancer and cardiovascular diseases

Research Abstract:

Dr. Shokeen’s projects include development and evaluation of small- and macro-molecular agents for multi-modal molecular imaging of cancer and cardiovascular diseases. Dr. Shokeen has designed in vitro cell assays to screen novel cell surface receptor targeted constructs including nanoparticles to investigate ligand-receptor structure-activity relationships in biologically relevant environments. The in vitro evaluations are a key bridge to in vivo applications in her research. One of Dr. Shokeen’s cancer imaging projects involve development and evaluation of very late antigen-4 (VLA-4) targeted PET radiopharmaceuticals for non- invasive molecular imaging of multiple myeloma. She recently published her findings involving the molecular imaging of hematopoietic progenitor cells (HPCs) that localize in the pre-metastatic niche prior to migration of tumor cells in metastatic mouse models of breast cancer. Dr. Shokeen’s projects seek to bring in the strengths of PET, MRI and Optical imaging techniques. In one of her cardiac imaging projects, Dr. Shokeen is using tomographic optical modalities for targeted molecular imaging of atherosclerotic plaques in pre-clinical animal models. Dr. Shokeen has active clinical collaborations within the oncology, cardiology and pathology departments

Selected Publications:

Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.
Soodgupta D, Zhou H, Beaino W, Lu L, Rettig M, Snee M, Skeath J, DiPersio JF, Akers WJ, Laforest R, Anderson CJ, Tomasson MH, Shokeen M.
J Nucl Med. 2016 Apr;57(4):640-5. doi: 10.2967/jnumed.115.164624. Epub 2016 Jan 7.
PMID: 26742713

New Approaches to Molecular Imaging of Multiple Myeloma.
Vij R, Fowler KJ, Shokeen M.
J Nucl Med. 2016 Jan;57(1):1-4. doi: 10.2967/jnumed.115.163808. Epub 2015 Nov 5. Review.
PMID: 26541780

Utilizing the Multiradionuclide Resolving Power of SPECT and Dual Radiolabeled Single Molecules to Assess Treatment Response of Tumors.
Xu B, Shokeen M, Sudlow GP, Harpstrite SE, Liang K, Cheney PP, Edwards WB, Sharma V, Laforest R, Akers WJ, Achilefu S.
Mol Imaging Biol. 2015 Oct;17(5):671-9. doi: 10.1007/s11307-015-0842-8.
PMID: 25790774

Noninvasive imaging of focal atherosclerotic lesions using fluorescence molecular tomography.
Maji D, Solomon M, Nguyen A, Pierce RA, Woodard PK, Akers WJ, Achilefu S, Culver JP, Abendschein DR, Shokeen M.
J Biomed Opt. 2014;19(11):110501. doi: 10.1117/1.JBO.19.11.110501.
PMID: 25389566

Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.
Soodgupta D, Hurchla MA, Jiang M, Zheleznyak A, Weilbaecher KN, Anderson CJ, Tomasson MH, Shokeen M.
PLoS One. 2013;8(2):e55841. doi: 10.1371/journal.pone.0055841. Epub 2013 Feb 8. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/8532e291-73d3-461c-810d-0533ccb1eba0.
PMID: 23409060

Comparison of two cross-bridged macrocyclic chelators for the evaluation of 64Cu-labeled-LLP2A, a peptidomimetic ligand targeting VLA-4-positive tumors.
Jiang M, Ferdani R, Shokeen M, Anderson CJ.
Nucl Med Biol. 2013 Feb;40(2):245-51. doi: 10.1016/j.nucmedbio.2012.10.010. Epub 2012 Dec 23.
PMID: 23265977

Last Updated: 7/11/2016 2:24:00 PM

Back To Top

Follow us: